Kidney diseases, including acute kidney injury (AKI) and chronic kidney disease (CKD), have emerged as one of the most prominent causes of death and suffering in the 21st century. The high number of affected individuals and the significant adverse impacts of kidney diseases call for enhanced efforts for better prevention and treatment.
Despite the available treatments being used widely in clinical, therapeutic strategies that treat AKI, inhibit AKI-CKD transition, and mitigate the progression of CKD to inevitable renal replacement therapy are still lacking. Intensive research has been conducted in order to limit the prevalence and progression of kidney diseases. During the past decade, a better understanding of the pathophysiological mechanisms of kidney diseases has highlighted the benefits of targeted therapy.
Nowadays multiple preclinical and clinical studies demonstrate the promise of the successful use of targeted therapies for kidney diseases. In addition, targeted drug delivery systems have attracted attention as they comprise the systemic delivery of a drug carrier system to specific cell types, tissues or organs. The application of targeted therapy makes the treatment of kidney diseases more specific, less side effects and is personalized to each patient.
The purpose of this research topic is to support the identification of druggable targets, the availability of new therapeutic approaches, the development of preclinical and clinical trials to limit the occurrence and progression of kidney diseases, including both AKI and CKD. We aim to collect manuscripts on kidney diseases, including original research articles, reviews, and case reports about but not limited to the followings:
? The basic study for the identification of “druggable” targets
? The clinical trials associated with the therapy of AKI and CKD
? The studies for the availability of novel therapeutic approaches, for example, the novel targeted drug delivery systems
Kidney diseases, including acute kidney injury (AKI) and chronic kidney disease (CKD), have emerged as one of the most prominent causes of death and suffering in the 21st century. The high number of affected individuals and the significant adverse impacts of kidney diseases call for enhanced efforts for better prevention and treatment.
Despite the available treatments being used widely in clinical, therapeutic strategies that treat AKI, inhibit AKI-CKD transition, and mitigate the progression of CKD to inevitable renal replacement therapy are still lacking. Intensive research has been conducted in order to limit the prevalence and progression of kidney diseases. During the past decade, a better understanding of the pathophysiological mechanisms of kidney diseases has highlighted the benefits of targeted therapy.
Nowadays multiple preclinical and clinical studies demonstrate the promise of the successful use of targeted therapies for kidney diseases. In addition, targeted drug delivery systems have attracted attention as they comprise the systemic delivery of a drug carrier system to specific cell types, tissues or organs. The application of targeted therapy makes the treatment of kidney diseases more specific, less side effects and is personalized to each patient.
The purpose of this research topic is to support the identification of druggable targets, the availability of new therapeutic approaches, the development of preclinical and clinical trials to limit the occurrence and progression of kidney diseases, including both AKI and CKD. We aim to collect manuscripts on kidney diseases, including original research articles, reviews, and case reports about but not limited to the followings:
? The basic study for the identification of “druggable” targets
? The clinical trials associated with the therapy of AKI and CKD
? The studies for the availability of novel therapeutic approaches, for example, the novel targeted drug delivery systems
